In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?

Executive Summary

NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?

You may also be interested in...

NicOx Blood Pressure Data Positive, But Is it Enough?

Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod

NicOx Data Positive, But Is it Enough?

NicOx reported positive blood pressure data for Phase III osteoarthritis candidate naproxcinod, but pooled, post-hoc analyses may not be enough to differentiate the drug.

NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod

In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts